Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHST001 in Advanced Solid Tumors
NCT06840886Phase 1Recruiting
- Sponsor
- Pheast Therapeutics
- Start
- Mar 2025
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PHST001 in solid tumor, ovarian cancer, endometrial cancer (EC) and 6 more (10 arms), sponsored by Pheast Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 21 days, Serious Adverse Events at 90 days and 6 more. Started Mar 2025; status: recruiting.
02
Drugs
PHST001
03
Conditions
solid tumorovarian cancerendometrial cancer (EC)cholangiocarcinoma (CCA)central nervous system tumor
Beyond the preview
Go deeper on NCT06840886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840886.